[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484374":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":38,"centralContacts":43,"locations":49,"responsibleParty":66,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":37,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":37,"enrollmentInfo":81,"targetDuration":37,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":37,"overallStatus":52,"whyStopped":37,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Asociación para Evitar la Ceguera en México","OTHER",[8,14,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment at time of surgery","EXPERIMENTAL","EO2002 intracameral injection",[13],"Biological: EO2002",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment post surgery",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Treatment at time of or post surgery","ACTIVE_COMPARATOR",[13],{"label":22,"type":23,"description":24,"interventionNames":25},"Sham injection at time of or post surgery","SHAM_COMPARATOR","Sham injection",[26],"Other: Sham injection",[28,35],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"BIOLOGICAL","EO2002","Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery",[18,9,15],[34],"Magnetic Human Corneal Endothelial Cells",{"type":6,"name":24,"description":24,"armGroupLabels":36,"otherNames":37},[22],null,[39],{"name":40,"affiliation":41,"role":42},"Valeria Sanchez Huerta, MD","Asociacion para Evitar la Ceguera","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":37,"email":48},"Yara Luna","CONTACT","55 39 53 12 25","reclutamiento.proyectos@apec.com.mx",[50],{"facility":51,"status":52,"city":53,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Asociacion para Evitar la Ceguera en Mexico","RECRUITING","Mexico City","04030","Mexico","MX",{"type":58,"coordinates":59},"Point",[60,61],-99.12766,19.42847,{"lat":61,"lon":60},[64],{"name":45,"role":46,"phone":65,"phoneExt":37,"email":48},"55 39 53 1225",{"type":67,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[69],{"name":70,"class":71},"Emmecell","INDUSTRY","100484374","phase-1-safety-and-tolerability-of-eo2002-100484374",false,"NCT05587205","Safety and Tolerability of EO2002","Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery","Key Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.\n3. Decreased endothelial cell count\n\nExclusion Criteria:\n\nAll ocular criteria apply to study eye unless otherwise noted.\n\n1. Other corneal disease\n2. Macular disease that in the investigator and\u002For sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.\n3. Descemet membrane detachment.\n4. History of uveitis or other ocular inflammatory disease.\n5. History of incisional glaucoma surgery\n6. Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.\n7. History of ocular neoplasm.\n8. ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20\u002F200).\n9. Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.\n10. Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.\n11. Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.","ALL","18 Years",{"count":82,"type":83},32,"ESTIMATED","INTERVENTIONAL",[86],"PHASE1","The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.",[89,90],"Cataract","Endothelial Cell Loss, Corneal","2025-12-02",{"date":93,"type":94},"2025-12-08","ACTUAL",{"date":96,"type":94},"2022-08-30",{"date":98,"type":83},"2026-10-06",{"name":5,"class":6},1]